Showing results (31-40 of 98) with videos related to

Sort By:
Pageof 10
Antimicrobial Agents and Chemotherapy|March 16, 2011
In vitro activity of ceftaroline against gram-positive and gram-negative pathogens isolated from patients in Canadian hospitals in 2009James A Karlowsky, Heather J Adam, Melanie R Decorby, et al.
The Journal of Antimicrobial Chemotherapy|August 28, 2025
Comparison of antimicrobial resistance and serotype patterns in Streptococcus pneumoniae from blood cultures and respiratory specimens in Canadian hospitals from the CANWARD study (2007-23)Heather J Adam, Alyssa R Golden, Irene Martin, et al.
Diagnostic Microbiology and Infectious Disease|February 5, 2017
In vitro activity of Oritavancin against gram-positive pathogens isolated in Canadian hospital laboratories from 2011 to 2015James A Karlowsky, Andrew J Walkty, Melanie R Baxter, et al.
The Journal of Antimicrobial Chemotherapy|March 25, 2025
Comparing serotype coverage of pneumococcal vaccines with PCV21 (V116), a new 21-valent conjugate pneumococcal vaccine, and the epidemiology of its eight unique Streptococcus pneumoniae serotypes (15A, 15C, 16F, 23A, 23B, 24F, 31 and 35B) causing invasive pneumococcal disease in adult patients in Canada: SAVE study, 2018-21John J Schellenberg, Heather J Adam, Melanie R Baxter, et al.
Journal of Clinical Microbiology|August 21, 2020
Susceptibility of Clinical Isolates of Escherichia coli to Fosfomycin as Measured by Four In Vitro Testing MethodsJames A Karlowsky, Philippe R S Lagacé-Wiens, Nancy M Laing, et al.
Journal of the Association of Medical Microbiology and Infectious Disease Canada = Journal Officiel De L'Association Pour La Microbiologie Medicale Et L'Infectiologie Canada|November 7, 2022
In vitro susceptibility of common bacterial pathogens causing respiratory tract infections in Canada to lefamulin, a new pleuromutilinRobert M Taylor, James A Karlowsky, Melanie R Baxter, et al.
The Journal of Antimicrobial Chemotherapy|February 10, 2022
PCV-15 and PPSV-23 coverage of invasive and respiratory tract Streptococcus pneumoniae, including MDR and XDR isolates: CANWARD 2007-20Alyssa R Golden, Melanie Baxter, Heather J Adam, et al.
The Journal of Antimicrobial Chemotherapy|April 26, 2006
Comparative in vitro activity of PGE 9262932 and fluoroquinolones against Canadian clinical Streptococcus pneumoniae isolates, including molecularly characterized ciprofloxacin-resistant isolatesHeather J Adam, Kristen N Schurek, Melanie R Decorby, et al.
Diagnostic Microbiology and Infectious Disease|March 1, 2011
Characterization of Acinetobacter baumannii and meropenem-resistant Pseudomonas aeruginosa in Canada: results of the CANWARD 2007-2009 studyMelissa McCracken, Laura F Mataseje, Vivian Loo, et al.
Vaccine|August 29, 2021
Whole genome characterization of Streptococcus pneumoniae from respiratory and blood cultures collected from Canadian hospitals before and after PCV-13 implementation in Canada: Focus on serotypes 22F and 33F from CANWARD 2007-2018Alyssa R Golden, Heather J Adam, Melanie Baxter, et al.
Pageof 10